

# Carmine Savoia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3494759/publications.pdf>

Version: 2024-02-01

84  
papers

3,903  
citations

147566

31  
h-index

123241

61  
g-index

87  
all docs

87  
docs citations

87  
times ranked

5307  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 115-123.	1.0	44
2	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	1.0	9
3	Hypertension, a Moving Target in COVID-19. Circulation Research, 2021, 128, 1062-1079.	2.0	61
4	Carbohydrates and Hypertension: The Quality Counts. Hypertension, 2021, 78, 431-433.	1.3	5
5	Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. Journal of Hypertension, 2021, 39, 169-180.	0.3	2
6	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Frontiers in Medicine, 2021, 8, 798958.	1.2	88
7	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. Hypertension, 2020, 76, 1753-1761.	1.3	19
8	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.0	4
9	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	1.3	330
10	Vascular Aging and Central Aortic Blood Pressure: From Pathophysiology to Treatment. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 299-308.	1.0	19
11	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	1.0	37
12	Altered Tregs Differentiation and Impaired Autophagy Correlate to Atherosclerotic Disease. Frontiers in Immunology, 2020, 11, 350.	2.2	8
13	Role of Inflammation in Microvascular Damage. Updates in Hypertension and Cardiovascular Protection, 2020, , 73-83.	0.1	0
14	SP569ASSESSMENT OF ARTERIAL STIFFNESS IN A POPULATION OF PATIENTS ON CHRONIC HEMODIALYSIS: PROSPECTIVE CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
15	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. Cardiovascular Research, 2019, 116, 429-437.	1.8	20
16	VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. Hypertension, 2018, 71, 638-647.	1.3	73
17	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. Hypertension, 2018, 71, 1193-1200.	1.3	22
18	Natural History of Treated and Untreated Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 33-44.	0.1	6

#	ARTICLE	IF	CITATIONS
19	Hypertension, Diabetes Mellitus, and Excess Cardiovascular Risk. <i>Hypertension</i> , 2017, 70, 882-883.	1.3	6
20	Personalized medicine—a modern approach for the diagnosis and management of hypertension. <i>Clinical Science</i> , 2017, 131, 2671-2685.	1.8	59
21	Immune Cells in Cardiovascular Disease: Has the Time Arrived for New Targets in Human Hypertension?. <i>American Journal of Hypertension</i> , 2017, 30, 21-23.	1.0	3
22	Microvascular Alterations in Hypertension and Vascular Aging. <i>Current Hypertension Reviews</i> , 2017, 13, 16-23.	0.5	22
23	c-Src Inhibition Improves Cardiovascular Function but not Remodeling or Fibrosis in Angiotensin II-Induced Hypertension. <i>Hypertension</i> , 2016, 68, 1179-1190.	1.3	27
24	Dual renin-angiotensin system blockade and vascular remodeling. <i>Journal of Hypertension</i> , 2015, 33, 2392-2394.	0.3	1
25	AT1R-AT2R Cross Talk. , 2015, , 35-39.		2
26	Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention. <i>Current Hypertension Reports</i> , 2015, 17, 553.	1.5	5
27	Vascular Changes in the Microcirculation: Arterial Remodeling and Capillary Rarefaction. , 2015, , 69-79.		1
28	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 353-63.	0.7	11
29	Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 7487-96.	1.3	1
30	Reply to Letter by McIntyre et al.. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1733.e3.	0.8	0
31	Impact of the Direct Angiotensin II Type 2 Receptor Stimulation on Renal Function. <i>Hypertension</i> , 2014, 64, 227-228.	1.3	1
32	Evaluation of microvascular structure in humans. <i>Journal of Hypertension</i> , 2014, 32, 2120-2129.	0.3	53
33	Effects of a Long-Term Treatment With Aliskiren or Ramipril on Structural Alterations of Subcutaneous Small-Resistance Arteries of Diabetic Hypertensive Patients. <i>Hypertension</i> , 2014, 64, 717-724.	1.3	25
34	Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome. <i>Canadian Journal of Cardiology</i> , 2014, 30, 534-543.	0.8	110
35	Abstract MP10: Early Functional and Structural Alterations of Resistance Arteries in Mice Treated with an Inhibitor of the Vascular Endothelial Growth Factor Receptor. <i>Hypertension</i> , 2014, 64, .	1.3	0
36	The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes. <i>Clinical Science</i> , 2013, 125, 183-189.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Abstract 45: Reduced Vascular Remodeling and Improved Endothelial Function in Transglutaminase 2 Knock-Out Mice Treated with Angiotensin II. Hypertension, 2013, 62, .	1.3	0
38	Abstract 406: Improved Angiotensin II Type 2 Receptor Expression and Function in Transglutaminase 2 Knock-Out Mice Treated with Angiotensin II. Hypertension, 2013, 62, .	1.3	0
39	Exercise activity and endothelial function. Journal of Hypertension, 2012, 30, 2083-2084.	0.3	4
40	The key role of microvascular structure assessment in treated hypertensive patients. Journal of Hypertension, 2012, 30, 688-690.	0.3	3
41	Abstract 533: MAS Receptor Activation Contributes to the Improvement of Vascular Remodeling During Chronic Angiotensin II Type 1 Receptor Blockade in Angiotensin II Type 2 Receptor Knockout Mice.. Hypertension, 2012, 60, .	1.3	0
42	High Blood Pressure, Ventricular Tachycardia and Transient Left Ventricular Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 57-59.	1.0	2
43	Vascular Inflammation and Endothelial Dysfunction in Experimental Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	115
44	Angiotensin type 2 receptor in hypertensive cardiovascular disease. Current Opinion in Nephrology and Hypertension, 2011, 20, 125-132.	1.0	37
45	Angiotensin receptor modulation and cardiovascular remodeling. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 381-384.	1.0	9
46	Angiotensin II and the vascular phenotype in hypertension. Expert Reviews in Molecular Medicine, 2011, 13, e11.	1.6	152
47	Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clinical Science, 2010, 118, 231-240.	1.8	31
48	Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clinical Science, 2010, 118, 583-592.	1.8	14
49	Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. Journal of Hypertension, 2009, 27, 1804-1813.	0.3	21
50	Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients. Hypertension, 2008, 51, 432-439.	1.3	156
51	Vasoactive peptides in cardiovascular (patho)physiology. Expert Review of Cardiovascular Therapy, 2007, 5, 531-552.	0.6	39
52	Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension, 2007, 49, 341-346.	1.3	125
53	Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. Journal of the American Society of Hypertension, 2007, 1, 189-199.	2.3	25
54	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science, 2007, 112, 375-384.	1.8	276

#	ARTICLE	IF	CITATIONS
55	Angiotensin Type 2 Receptors in the Cardiovascular System. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 63-68.	1.0	1
56	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 103-110.	1.0	0
57	Reduction of C-reactive protein and the use of anti-hypertensives. Vascular Health and Risk Management, 2007, 3, 975-83.	1.0	24
58	Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Journal of Hypertension, 2006, 24, 2417-2422.	0.3	70
59	Inflammation in hypertension. Current Opinion in Internal Medicine, 2006, 5, 245-251.	1.5	175
60	Inhibition of the renin angiotensin system: Implications for the endothelium. Current Diabetes Reports, 2006, 6, 274-278.	1.7	35
61	Response to Are the Eutrophic Effects of Angiotensin Receptor Blockers Real?. Hypertension, 2006, 48, .	1.3	0
62	Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. Hypertension, 2006, 48, 271-277.	1.3	88
63	Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2005, 23, 1037-1045.	0.3	92
64	Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents'. European Heart Journal, 2005, 27, 1506-1507.	1.0	4
65	Transient Receptor Potential Melastatin 7 Ion Channels Regulate Magnesium Homeostasis in Vascular Smooth Muscle Cells. Circulation Research, 2005, 96, 207-215.	2.0	185
66	Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. American Journal of Hypertension, 2005, 18, 493-499.	1.0	107
67	Deletion of p66 shc Gene Protects Against Age-Related Endothelial Dysfunction. Circulation, 2004, 110, 2889-2895.	1.6	276
68	Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment. Hypertension, 2004, 43, 399-404.	1.3	107
69	Differential Calcium Regulation by Hydrogen Peroxide and Superoxide in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2004, 44, 200-208.	0.8	127
70	Eplerenone Prevents Salt-Induced Vascular Remodeling and Cardiac Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2004, 43, 1252-1257.	1.3	103
71	Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Medical Clinics of North America, 2004, 88, 39-62.	1.1	14
72	New Frontiers in Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 41-46.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Altered regulation of endothelin A receptor subtype in the cerebral arterioles in response to a Japanese-style diet, in stroke-prone hypertensive rats. <i>Journal of Hypertension</i> , 2003, 21, 105-113.	0.3	5
74	Angiotensin II AT2 receptor subtype. <i>Journal of Hypertension</i> , 2003, 21, 1429-1443.	0.3	89
75	The Renin-Angiotensin System as a Risk Factor and Therapeutic Target for Cardiovascular and Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S173-S178.	3.0	87
76	Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. <i>Journal of Hypertension</i> , 2002, 20, 693-699.	0.3	31
77	AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan. <i>American Journal of Hypertension</i> , 2002, 15, A13.	1.0	1
78	Endothelial Dysfunction and Stroke. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S75-S78.	0.8	59
79	Role of angiotensin II AT 1 and AT 2 subtype receptors in the regulation of atrial natriuretic peptide expression in salt-restricted rats. <i>Basic Research in Cardiology</i> , 2000, 95, 64-69.	2.5	2
80	Defective suppression of the aldosterone biosynthesis during stroke permissive diet in the stroke-prone phenotype of the spontaneously hypertensive rat. <i>Basic Research in Cardiology</i> , 2000, 95, 84-92.	2.5	6
81	Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. <i>Journal of Hypertension</i> , 1999, 17, 1873-1877.	0.3	52
82	Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1998, 16, 151-156.	0.3	12
83	Opposite Feedback Control of Renin and Aldosterone Biosynthesis in the Adrenal Cortex by Angiotensin II AT 1 -Subtype Receptors. <i>Hypertension</i> , 1997, 30, 563-568.	1.3	26
84	Role of Tissue Renin in the Regulation of Aldosterone Biosynthesis in the Adrenal Cortex of Nephrectomized Rats. <i>Circulation Research</i> , 1997, 81, 857-864.	2.0	26